Abstract
For the past 25 years, it has been known that alterations in DNA methylation (DNAm) occur in cancer, including hypomethylation of oncogenes and hypermethylation of tumor suppressor genes. However, most studies of cancer methylation have assumed that functionally important DNAm will occur in promoters, and that most DNAm changes in cancer occur in CpG islands. Here we show that most methylation alterations in colon cancer occur not in promoters, and also not in CpG islands, but in sequences up to 2 kb distant, which we term 'CpG island shores'. CpG island shore methylation was strongly related to gene expression, and it was highly conserved in mouse, discriminating tissue types regardless of species of origin. There was a notable overlap (45–65%) of the locations of colon cancer–related methylation changes with those that distinguished normal tissues, with hypermethylation enriched closer to the associated CpG islands, and hypomethylation enriched further from the associated CpG island and resembling that of noncolon normal tissues. Thus, methylation changes in cancer are at sites that vary normally in tissue differentiation, consistent with the epigenetic progenitor model of cancer, which proposes that epigenetic alterations affecting tissue-specific differentiation are the predominant mechanism by which epigenetic changes cause cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
206,07 € per year
only 17,17 € per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout








Similar content being viewed by others
Accession codes
References
Feinberg, A.P. & Vogelstein, B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301, 89–92 (1983).
Feinberg, A.P. & Tycko, B. The history of cancer epigenetics. Nat. Rev. Cancer 4, 143–153 (2004).
Baylin, S.B. & Ohm, J.E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer 6, 107–116 (2006).
Irizarry, R.A. et al. Comprehensive high-throughput arrays for relative methylation (CHARM). Genome Res. 18, 771–779 (2008).
Gardiner-Garden, M. & Frommer, M. CpG islands in vertebrate genomes. J. Mol. Biol. 196, 261–282 (1987).
Eckhardt, F. et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat. Genet. 38, 1378–1385 (2006).
Weber, M. et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat. Genet. 39, 457–466 (2007).
Illingworth, R. et al. A novel CpG island set identifies tissue-specific methylation at developmental gene loci. PLoS Biol. 6, e22 (2008).
Shen, L. et al. Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet. 3, 2023–2036 (2007).
Antequera, F. & Bird, A. CpG islands as genomic footprints of promoters that are associated with replication origins. Curr. Biol. 9, R661–R667 (1999).
Ehrlich, M. DNA methylation in cancer: too much, but also too little. Oncogene 21, 5400–5413 (2002).
Hong, C. et al. Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth. Proc. Natl. Acad. Sci. USA 104, 10974–10979 (2007).
Strathdee, G. et al. Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin. Cancer Res. 13, 5048–5055 (2007).
Cantor, A.B. et al. Antagonism of FOG-1 and GATA factors in fate choice for the mast cell lineage. J. Exp. Med. 205, 611–624 (2008).
Segditsas, S. et al. Putative direct and indirect Wnt targets identified through consistent gene expression changes in APC-mutant intestinal adenomas from humans and mice. Hum. Mol. Genet. 17, 3864–3875 (2008).
Jaeger, J. et al. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin. Cancer Res. 13, 806–815 (2007).
Seal, S. et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat. Genet. 38, 1239–1241 (2006).
Pedersen, I.S. et al. Frequent loss of imprinting of PEG1/MEST in invasive breast cancer. Cancer Res. 59, 5449–5451 (1999).
Gius, D. et al. Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell 6, 361–371 (2004).
Shiraki, T. et al. Cap analysis gene expression for high-throughput analysis of transcriptional starting point and identification of promoter usage. Proc. Natl. Acad. Sci. USA 100, 15776–15781 (2003).
Wakaguri, H., Yamashita, R., Suzuki, Y., Sugano, S. & Nakai, K. DBTSS: database of transcription start sites, progress report 2008. Nucleic Acids Res. 36, D97–D101 (2008).
Glass, J.L. et al. CG dinucleotide clustering is a species-specific property of the genome. Nucleic Acids Res. 35, 6798–6807 (2007).
Feinberg, A.P., Ohlsson, R. & Henikoff, S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 7, 21–33 (2006).
Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Statist Soc B (Methodol.) 57, 289–300 (1995).
Storey, J.D. The positive false discovery rate: a Bayesian interpretation and the q-value. Ann. Statist. 31, 2013–2035 (2003).
Irizarry, R.A. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249–264 (2003).
Bullmore, E.T. et al. Global, voxel, and cluster tests, by theory and permutation, for a difference between two groups of structural MR images of the brain. IEEE Trans. Med. Imaging 18, 32–42 (1999).
Efron, B., Tibshirani, R., Storey, J.D. & Tusher, V. Empirical Bayes analysis of a microarray experiment. J. Am. Stat. Assoc. 96, 1151–1160 (2001).
Tost, J. & Gut, I.G. DNA methylation analysis by pyrosequencing. Nat. Protocols 2, 2265–2275 (2007).
Higgs, B.W. et al. An online database for brain disease research. BMC Genomics 7, 70 (2006).
Bolstad, B.M., Irizarry, R.A., Astrand, M. & Speed, T.P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185–193 (2003).
Livak, K.J. & Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Methods 25, 402–408 (2001).
Gentleman, R.C. et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80 (2004).
Falcon, S. & Gentleman, R. Using GOstats to test gene lists for GO term association. Bioinformatics 23, 257–258 (2007).
Acknowledgements
We thank B. Volgelstein (Johns Hopkins University School of Medicine) for providing colon tumors and matched normal mucosa samples. Postmortem brain, liver and spleen tissue was donated by The Stanley Medical Research Institute collection courtesy of M.B. Knable, E.F. Torrey and R.H. Yolken, whom we also thank for making available gene expression data for the brain and the liver tissue. We thank B. Carvalho for help with statistical software and C. Crainiceanu for advice with statistical methods. This work was supported by US National Institutes of Health grants P50HG003233 (A.P.F.), R37CA54358 (A.P.F.) and 5R01RR021967 (R.A.I.).
Author information
Authors and Affiliations
Contributions
R.A.I. and A.P.F. designed the study and interpreted the results; R.A.I. designed new CHARM arrays and statistical methods with Z.W.; C.L.-A. performed bisulfite pyrosequencing, real-time quantitative PCR and sample preparation with C.M., K.G., M.R. and H.J.; B.W. and S.S. performed CHARM assays with sample preparation from M.W. and advice from J.B.P.; P.O. and H.C. performed functional assays; A.P.F. supervised the laboratory experiments and wrote the paper with R.A.I. and C.L.-A.
Corresponding authors
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–5, Supplementary Tables 1–7 and Supplementary Methods (PDF 541 kb)
Supplementary Data 1
Excel file of T-DMRs (XLS 3629 kb)
Supplementary Data 2
Excel file of C-DMRs (XLS 696 kb)
Supplementary Data 3
Gene expression data from 5-aza-2′ deoxycytidine/DKO experiments and gene expression data for genes associated with T-DMRs (XLS 40 kb)
Supplementary Data 4
Excel file of C-DMRs that are also T-DMRs; and C-DMRs that distinguish all the tumors from normal (XLS 284 kb)
Supplementary Data 5
Mus musculus T-DMRs (XLS 3273 kb)
Rights and permissions
About this article
Cite this article
Irizarry, R., Ladd-Acosta, C., Wen, B. et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 41, 178–186 (2009). https://doi.org/10.1038/ng.298
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.298
This article is cited by
-
Blood FOLR3 methylation dysregulations and heterogeneity in non-small lung cancer highlight its strong associations with lung squamous carcinoma
Respiratory Research (2024)
-
DNA methylome, R-loop and clinical exome profiling of patients with sporadic amyotrophic lateral sclerosis
Scientific Data (2024)
-
Epigenetics and stroke: role of DNA methylation and effect of aging on blood–brain barrier recovery
Fluids and Barriers of the CNS (2023)
-
Comprehensive analyses of partially methylated domains and differentially methylated regions in esophageal cancer reveal both cell-type- and cancer-specific epigenetic regulation
Genome Biology (2023)
-
The landscape of PBMC methylome in canine mammary tumors reveals the epigenetic regulation of immune marker genes and its potential application in predicting tumor malignancy
BMC Genomics (2023)